Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938751 | 0.83 | LMNA (0.42) | LMNAMEN1ALDH1A1MAPTALOX12 | |
| SCHEMBL10512812 | 0.83 | CNR2 (0.40) | CNR2LMNAMEN1ALDH1A1MAPT | |
| SCHEMBL9688839 | 0.81 | SMN1; SMN2 (0.44) | CNR2LMNAMEN1ALDH1A1MAPT | |
| SCHEMBL18322299 | 0.81 | KDM4E (0.41) | CNR2LMNAMEN1ALDH1A1MAPT | |
| SCHEMBL10536893 | 0.80 | CNR2 (0.38) | CNR2LMNAMEN1ALDH1A1MAPT | |
| SCHEMBL5252375 | 0.80 | CNR2 (0.43) | CNR2LMNAMEN1ALDH1A1MAPT | |
| SCHEMBL28703124 | 0.79 | HTT (0.44) | CNR2LMNAMEN1ALDH1A1MAPT | |
| SCHEMBL3998515 | 0.79 | CNR2 (0.42) | CNR2LMNAMEN1ALDH1A1MAPT | |
| SCHEMBL28709452 | 0.79 | CNR2 (0.45) | CNR2MEN1KMT2AKDM4E | |
| SCHEMBL3504148 | 0.79 | LMNA (0.41) | CNR2LMNAMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8558009-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2013-10-15 | — | — | US | disclosed |
| US-8212057-B2 | Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2012-07-03 | — | — | US | disclosed |
| US-8110598-B2 | (+-) Ethyl 3-{4-[2-(pyrrol-1-yl)ethoxy]phenyl}-2-ethoxypropanoate; hyperlipidaemia, hypercholesteremia, hyperglycemia, obesity, impaired glucose intolerance, leptin resistance, insulin resistance, reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids in the plasma | CADILA HEALTHCARE LIMITED (IN) | 2012-02-07 | — | — | US | disclosed |
| US-20110275669-A1 | Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2011-11-10 | — | — | US | disclosed |
| EP-1414439-B1 | NOVEL PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILA HEALTHCARE LTD (IN) | 2011-05-04 | — | — | EP | disclosed |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CADILLA HEALTHCARE LIMITED (IN) | 2008-08-07 | — | — | US | disclosed |
| US-7323491-B2 | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2008-01-29 | — | — | US | disclosed |
| US-20070238776-A1 | Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine | CADILLA HEALTHCARE LIMITED (IN) | 2007-10-11 | — | — | US | disclosed |
| US-7041837-B2 | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2006-05-09 | — | — | US | disclosed |
| US-6987123-B2 | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2006-01-17 | — | — | US | disclosed |
| US-20040186099-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | LOHRAY BRAJ BHUSHAN (IN) | 2004-09-23 | — | — | US | disclosed |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | disclosed |
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199498-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CYP11B2, CYP11B1, MAPT | CNR2 833/4885LMNA 1550/4885MEN1 776/4885 |
| US-20110275669-A1 | Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine | CETP, LIPA, LIPC | CNR2 1597/4885LMNA 1461/4885MEN1 2099/4885 |
| US-20070238776-A1 | Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine | LIPC, CETP, PNLIP | CNR2 1864/4885LMNA 1728/4885MEN1 4085/4885 |
| US-20040186099-A1 | Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine | CYP11B2, CYP11B1, MAPT | CNR2 833/4885LMNA 1550/4885MEN1 776/4885 |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | LIPA, LIPC, CYP46A1 | CNR2 316/4885LMNA 578/4885MEN1 2436/4885 |
| US-20080188402-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE | CYP11B2, MAPT, CYP11B1 | CNR2 747/4885LMNA 1495/4885MEN1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.